3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
3
Ovarian Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Kidney Neoplasms
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Hematologic Neoplasms
1
Cytopenia
1
Congenital Bone Marrow Failure Syndromes
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Neoplasms
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Bone Marrow Failure Disorders
1
Interventions
pembrolizumab
6
cabozantinib
6
Nivolumab
5
Ipilimumab
5
Axitinib
5
Radiosurgery
3
Blood Specimen Collection
3
zimberelimab
2
lenvatinib
2
Ultrasonography
2
Radiotherapy
2
Biopsy
2
tislelizumab
1
polyethylene glycol 3350
1
pazopanib
1
palbociclib
1
orellanine
1
olaparib
1
gallium Ga 68 dotatate
1
fludarabine
1
cyclopropapyrroloindole
1
brodalumab
1
belzutifan
1
atezolizumab
1
anlotinib
1
adagrasib
1
Watchful Waiting
1
Vincristine
1
Therapeutics
1
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Kidney Neoplasms
×
Genetic Counseling
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled